BioCity Biopharma announced the initiation of a randomized, placebo-controlled Phase 2 clinical trial of its novel, oral endothelin A -receptor selective antagonist, SC0062, with the enrollment of two patients with IgA nephropathy (IgAN) in China (NCT05687890).
